Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 3
Locations
Russian Federation
Study Type
Interventional
Intervention
Insulin Humulin® NPH
Insulin Rinsulin® NPH
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring diabetes mellitus, insulin
Eligibility Criteria
Inclusion Criteria:
- Signed written consent
- Diabetes mellitus type 2
- Indications for Rinsulin NPH / Humalog NPH treatment
- Glycosylated hemoglobin (HbA1c) level of 6.5 to 12.0 % at screening (both values inclusive)
- Body mass index (BMI) of 18.0 to 35 kg/m2 at screening (both values inclusive).
- Female patients of childbearing potential who are willing to use two acceptable methods of contraception, (e.g., intra-uterine device plus condom, spermicidal gel plus condom, diaphragm plus condom, etc.), from the time of screening and for the duration of the trial, through trial completion.
Exclusion Criteria:
- Age less than 18 years old at screening
- Pregnant and breast-feeding women
- Need of administration of glucocorticoid therapy or any other therapy that may influence glucose level
- Administration of any immunosupressive drugs (Cyclosporinum, Methotrexatum)
- Serological evidence of human immunodeficiency virus (HIV), hepatitis B (HbSAg), hepatitis C (HCVAb) or antibodies to Treponema pallidum (syphilis) at screening.
- History of hypersensitivity to any of the active or inactive ingredients of the insulin/insulin analogue preparations used in the trial, OR history of significant allergic drug reactions.
- History of hematological disorders that can affect the reliability of HbA1c estimation (hemoglobinopathies, hemolytic anemia, etc.).
- History or presence of a medical condition or disease that in the investigator's opinion would embarrass glycemic control and completion of the study
- Presence of severe diabetes complications
- Receipt of another investigational drug in the 3 months prior to screening
- Acute psychiatric disorder or exacerbation of chronic psychiatric disorder at screening
- History or presence of drug abuse
- Positive test for addictive substance in urine at screening
Sites / Locations
- Chelyabinsk Railway Clinical Hospital
- Moscow Endocrinological Dispensary
- Moscow Clinical Hospital № 71
- Nizhny Novgorod Regional Clinical Hospital
- V.A. Baranov Republic Hospital
- City Polyclinic № 6
- City Hospital № 2
- City Polyclinic № 17
- Medical Sanitary Unit № 157
- Institute of Medical Research
- Research Center Eco-Safety
- Saint Petersburg State Diagnostic Center № 85
- Diabetes Center
- Clinical Hospital № 3
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Insulin Humulin® NPH
Insulin Rinsulin® NPH
Arm Description
Insulin Humulin® NPH twice daily, individually glucose-level based administered doses +/- 1,2 or 3 OADs in stable doses, started before enrollment
Insulin Rinsulin® NPH twice daily, individually glucose-level based administered doses +/- 1,2 or 3 OADs in stable doses, started before enrollment
Outcomes
Primary Outcome Measures
Antibody Response
Change from baseline in titer of antibodies to human insulin
Secondary Outcome Measures
Hypoglycemic episodes (glucose level < 3.9 mmol/l) frequency
Change in BMI from baseline
Occurrence of adverse events
Occurrence of Injection Site Reaction
Change in HbA1c from baseline
Change in fasting plasma glucose level from baseline
Change in fasting plasma glucose level from baseline
Change in fasting plasma glucose level from baseline
Change in basal insulin dose per body weight (U/kg) from baseline
Change in total basal insulin dose (U) from baseline
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04012775
Brief Title
Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients
Official Title
An Open-label, Randomized, Multi-center, Parallel-group Clinical Trial Comparing the Efficacy and Safety of Rinsulin® NPH ("Geropharm", Russia) With Humulin® NPH ("Lilly France", France) in Type 2 Diabetes Mellitus Patients
Study Type
Interventional
2. Study Status
Record Verification Date
January 2019
Overall Recruitment Status
Completed
Study Start Date
April 20, 2017 (Actual)
Primary Completion Date
September 24, 2018 (Actual)
Study Completion Date
September 24, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Geropharm
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The study is designed to approve non-inferior efficacy and safety of Rinsulin® NPH compared to Humulin® NPH.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
diabetes mellitus, insulin
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
201 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Insulin Humulin® NPH
Arm Type
Active Comparator
Arm Description
Insulin Humulin® NPH twice daily, individually glucose-level based administered doses +/- 1,2 or 3 OADs in stable doses, started before enrollment
Arm Title
Insulin Rinsulin® NPH
Arm Type
Experimental
Arm Description
Insulin Rinsulin® NPH twice daily, individually glucose-level based administered doses +/- 1,2 or 3 OADs in stable doses, started before enrollment
Intervention Type
Biological
Intervention Name(s)
Insulin Humulin® NPH
Intervention Description
4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
Intervention Type
Biological
Intervention Name(s)
Insulin Rinsulin® NPH
Intervention Description
4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
Primary Outcome Measure Information:
Title
Antibody Response
Description
Change from baseline in titer of antibodies to human insulin
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
Hypoglycemic episodes (glucose level < 3.9 mmol/l) frequency
Time Frame
28 weeks (4 + 24 weeks)
Title
Change in BMI from baseline
Time Frame
24 weeks
Title
Occurrence of adverse events
Time Frame
28 weeks (4 + 24 weeks)
Title
Occurrence of Injection Site Reaction
Time Frame
28 weeks (4 + 24 weeks)
Title
Change in HbA1c from baseline
Time Frame
24 weeks
Title
Change in fasting plasma glucose level from baseline
Time Frame
4 weeks
Title
Change in fasting plasma glucose level from baseline
Time Frame
16 weeks
Title
Change in fasting plasma glucose level from baseline
Time Frame
28 weeks
Title
Change in basal insulin dose per body weight (U/kg) from baseline
Time Frame
24 weeks
Title
Change in total basal insulin dose (U) from baseline
Time Frame
24 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Signed written consent
Diabetes mellitus type 2
Indications for Rinsulin NPH / Humalog NPH treatment
Glycosylated hemoglobin (HbA1c) level of 6.5 to 12.0 % at screening (both values inclusive)
Body mass index (BMI) of 18.0 to 35 kg/m2 at screening (both values inclusive).
Female patients of childbearing potential who are willing to use two acceptable methods of contraception, (e.g., intra-uterine device plus condom, spermicidal gel plus condom, diaphragm plus condom, etc.), from the time of screening and for the duration of the trial, through trial completion.
Exclusion Criteria:
Age less than 18 years old at screening
Pregnant and breast-feeding women
Need of administration of glucocorticoid therapy or any other therapy that may influence glucose level
Administration of any immunosupressive drugs (Cyclosporinum, Methotrexatum)
Serological evidence of human immunodeficiency virus (HIV), hepatitis B (HbSAg), hepatitis C (HCVAb) or antibodies to Treponema pallidum (syphilis) at screening.
History of hypersensitivity to any of the active or inactive ingredients of the insulin/insulin analogue preparations used in the trial, OR history of significant allergic drug reactions.
History of hematological disorders that can affect the reliability of HbA1c estimation (hemoglobinopathies, hemolytic anemia, etc.).
History or presence of a medical condition or disease that in the investigator's opinion would embarrass glycemic control and completion of the study
Presence of severe diabetes complications
Receipt of another investigational drug in the 3 months prior to screening
Acute psychiatric disorder or exacerbation of chronic psychiatric disorder at screening
History or presence of drug abuse
Positive test for addictive substance in urine at screening
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Olga A Miroshnichenko, PhD
Organizational Affiliation
Saint Petersburg State Diagnostic Center № 85
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chelyabinsk Railway Clinical Hospital
City
Chelyabinsk
ZIP/Postal Code
454000
Country
Russian Federation
Facility Name
Moscow Endocrinological Dispensary
City
Moscow
ZIP/Postal Code
119034
Country
Russian Federation
Facility Name
Moscow Clinical Hospital № 71
City
Moscow
ZIP/Postal Code
121374
Country
Russian Federation
Facility Name
Nizhny Novgorod Regional Clinical Hospital
City
Nizhny Novgorod
ZIP/Postal Code
603126
Country
Russian Federation
Facility Name
V.A. Baranov Republic Hospital
City
Petrozavodsk
ZIP/Postal Code
185000
Country
Russian Federation
Facility Name
City Polyclinic № 6
City
Saint Petersburg
ZIP/Postal Code
192148
Country
Russian Federation
Facility Name
City Hospital № 2
City
Saint Petersburg
ZIP/Postal Code
194354
Country
Russian Federation
Facility Name
City Polyclinic № 17
City
Saint Petersburg
ZIP/Postal Code
195176
Country
Russian Federation
Facility Name
Medical Sanitary Unit № 157
City
Saint Petersburg
ZIP/Postal Code
196066
Country
Russian Federation
Facility Name
Institute of Medical Research
City
Saint Petersburg
ZIP/Postal Code
196084
Country
Russian Federation
Facility Name
Research Center Eco-Safety
City
Saint Petersburg
ZIP/Postal Code
196143
Country
Russian Federation
Facility Name
Saint Petersburg State Diagnostic Center № 85
City
Saint Petersburg
ZIP/Postal Code
198260
Country
Russian Federation
Facility Name
Diabetes Center
City
Samara
ZIP/Postal Code
443067
Country
Russian Federation
Facility Name
Clinical Hospital № 3
City
Yaroslavl
ZIP/Postal Code
150007
Country
Russian Federation
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients
We'll reach out to this number within 24 hrs